Sources agree. The dateline is Helsinki, Finland, but the source does not state that Helsinki, Finland is Kasvu Therapeutics' headquarters; Business Finland is described separately as providing strategic funding rather than participating in this Series A.
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: announces "Series A" funding round led by·[ SCRAPE ]4 pages read: fidelity.com, globenewswire.com, manilatimes.net·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back across 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]dossier built by the Firecrawl agent
Sources agree. The dateline is Helsinki, Finland, but the source does not state that Helsinki, Finland is Kasvu Therapeutics' headquarters; Business Finland is described separately as providing strategic funding rather than participating in this Series A.
[ BUILT WITH ]·[ ]
Dossier
[ CHECKED ]
Fetched today
Kasvu Therapeutics develops small-molecule TrkB neuroplastogens designed to treat neuropsychiatric and neurodegenerative disorders without the hallucinations associated with psychedelics.
Founders
Jami Mandelin · Co-founder, CEO
He has 14 years of commercial and R&D experience from Faron Pharmaceuticals, Novartis, and Roche.
Rafael Moliner · Co-founder, CSO
He has 12 years of experience in TrkB biology from the University of Helsinki.
Peter Gallagher · Co-founder, Medicinal Chemistry Lead
He has 36 years of medicinal-chemistry experience in CNS drug discovery from Eli Lilly and more than 20 patents.
Founded
2023
Backers
Tesi (Finnish Industry Investment), Business Finland
Kasvu Therapeutics sells neuroplastogens designed to treat neuropsychiatric and neurodegenerative disorders, targeting both medical professionals and patients.
Headcount
12
Type
Privately Held
Industry
Biotechnology Research
Via Alexandria from FullEnrich: headcount, type, industry
